Skip to main content

Syros Pharmaceuticals, Inc. (SYRS)

NASDAQ: SYRS · IEX Real-Time Price · USD
4.32 -0.03 (-0.69%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap270.02M
Revenue (ttm)19.52M
Net Income (ttm)-86.33M
Shares Out62.86M
EPS (ttm)-1.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume142,860
Open4.36
Previous Close4.35
Day's Range4.30 - 4.44
52-Week Range4.00 - 15.65
Beta1.92
AnalystsBuy
Price Target17.14 (+296.8%)
Est. Earnings DateNov 4, 2021

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial ...

IndustryBiotechnology
IPO DateJun 30, 2016
CEONancy Simonian
Employees103
Stock ExchangeNASDAQ
Ticker SymbolSYRS
Full Company Profile

Financial Performance

In 2020, SYRS's revenue was $15.09 million, an increase of 661.50% compared to the previous year's $1.98 million. Losses were -$84.04 million, 11.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 17.14, which is an increase of 296.76% from the latest price.

Price Target
$17.14
(296.76% upside)
Analyst Consensus: Buy

News

Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the gra...

1 week ago - Business Wire

Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Ch...

1 week ago - Business Wire

Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dos...

3 weeks ago - Business Wire

Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the gra...

3 weeks ago - Business Wire

Syros Announces Appointment of Conley Chee as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Conley Chee as t...

3 weeks ago - Business Wire

Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings

Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609. Updated data demonstrated clinical activity in heavily pre-treated ...

1 month ago - Benzinga

Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-56...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new data from the dose-escalation p...

1 month ago - Business Wire

Are Options Traders Betting on a Big Move in Syros (SYRS) Stock?

Investors need to pay close attention to Syros (SYRS) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new data from ...

1 month ago - Business Wire

Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire,...

1 month ago - Business Wire

Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitid...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dos...

1 month ago - Business Wire

Syros to Present at Upcoming Investor Conferences in September

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

1 month ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 0.00% and 12.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...

2 months ago - Business Wire

Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal C...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has entered into a clinical...

2 months ago - Business Wire

Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? What You Should Know

Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...

2 months ago - Business Wire

9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290%

Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other symbols:CDEVGTBPNCMIPRTK
3 months ago - PennyStocks

Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

4 months ago - Business Wire

7 Best Penny Stocks to Buy for Your June Buy List

Penny stocks are incredibly volatile financial vehicles not for the faint of heart. That said, you might win big with these offerings.

Other symbols:AESEGROYPLGSONMVISL
4 months ago - InvestorPlace

Reddit Penny Stocks You Might've Missed In May 2021

Former penny stocks on Reddit you might've overlooked this month The post Reddit Penny Stocks You Might've Missed In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other symbols:BTUGTBP
4 months ago - PennyStocks

Cathie Wood's ARK Invest Sells 3.6 Million Shares of Syros Pharma

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 3.6 million shares of Syros Pharmaceuticals Inc.

4 months ago - 24/7 Wall Street

Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it plans to host a three-part ...

5 months ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 58.18% and 58.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...

5 months ago - Business Wire